tbuckley/cabot-search huggingface dataset:
Characterization of CD34<sup>+</sup> hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination
Authors: A. Mayado, C. Teodosio, N. Dasilva‐Freire, M. Jara‐Acevedo, A. C. Garcia‐Montero, I. Álvarez‐Twose, L. Sánchez‐Muñoz, A. Matito, C. Caldas, J. I. Muñoz‐González, A. Henriques, J. I. Sánchez‐Gallego, L. Escribano, A. Orfao
Journal: Allergy (2018)

Recent studies show that most systemic mastocytosis (SM) patients, including indolent SM (ISM) with (ISMs+) and without skin lesions (ISMs-), carry the KIT D816V mutation in PB leukocytes. We investigated the potential association between the degree of involvement of BM hematopoiesis by the KIT D816V mutation and the distribution of different maturation-associated compartments of bone marrow (BM) and peripheral blood (PB) CD34+ hematopoietic precursors (HPC) in ISM and identified the specific PB cell compartments that carry this mutation.The distribution of different maturation-associated subsets of BM and PB CD34+ HPC from 64 newly diagnosed (KIT-mutated) ISM patients and 14 healthy controls was analyzed by flow cytometry. In 18 patients, distinct FACS-purified PB cell compartments were also investigated for the KIT mutation.ISM patients showed higher percentages of both BM and PB MC-committed CD34+ HPC vs controls, particularly among ISM cases with MC-restricted KIT mutation (ISMMC ); this was associated with progressive blockade of maturation of CD34+ HPC to the neutrophil lineage from ISMMC to multilineage KIT-mutated cases (ISMML ). Regarding the frequency of KIT-mutated cases and cell populations in PB, variable patterns were observed, the percentage of KIT-mutated PB CD34+ HPC, eosinophils, neutrophils, monocytes and T cells increasing from ISMs-MC and ISMs+MC to ISMML patients.The presence of the KIT D816V mutation in PB of ISM patients is associated with (early) involvement of circulating CD34+ HPC and multiple myeloid cell subpopulations, KIT-mutated PB CD34+ HPC potentially contributing to early dissemination of the disease.
Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol
Authors: Daniel Auclair, Sikander Ailawadhi, Jesus G. Berdeja, Xuhong Cao, Craig E. Cole, Craig C Hofmeister, Sundar Jagannath, Andrzej J. Jakubowiak, Amrita Krishnan, Shaji K Kumar, Moshe Levy, Sagar Lonial, Gregory Orloff, Dan Robinson, David Siegel, Suzanne Trudel, Saad Z Usmani, Ravi Vij, Jeffrey Lee Wolf, Jennifer Yesil, Jeffrey A Zonder, Arul Chinnaiyan, P. Leif Bergsagel
Journal: Blood (2017)
People at risk of familial hypercholesterolaemia should have DNA test, says NICE
Authors: Jacqui Thornton
Journal: BMJ (2017)

Primary care medical records should be systematically examined to identify people with familial hypercholesterolaemia, says updated guidance from the UK National Institute for Health and Care Excellence (NICE).1

Up to 260 000 people in the UK are thought to have the condition, but only a minority, around 15%, of cases have been diagnosed.2

NICE’s guideline recommends that records of patients who have a total cholesterol concentration greater than 7.5 mmol/L if they are under 30 years old or 9.0 mmol/L if they are aged 30 or over should be scrutinised.

NICE said that these thresholds …
Concordancia histológica de la biopsia previa y de la pieza de disección de las lesiones gástricas tratadas mediante disección submucosa endoscópica
Authors: M Gómez Alonso, M Rullán, J Carrascosa, D Oyón, A Elosua, S López, JF Juanmartiñena, L Uribarri, E Albéniz, JJ Vila
Journal: Endoscopy (2017)

Estudios previos de series orientales describen que en las lesiones gástricas es frecuente la discrepancia entre el diagnóstico anatomopatológico en la biopsia previa y el estudio final en la pieza de disección submucosa endoscópica (DSE).
Toll‐like receptor 5 signaling restrains T‐cell/natural killer T‐cell activation and protects against concanavalin A–induced hepatic injury
Authors: Lei Wang, Wen Zhang, Chang‐Hui Ge, Rong‐Hua Yin, Yang Xiao, Yi‐Qun Zhan, Miao Yu, Chang‐Yan Li, Zhi‐Qiang Ge, Xiao‐Ming Yang
Journal: Hepatology (2017)

Toll‐like receptor‐5 (TLR5) signaling regulates the immune privileged status of the liver and is involved in hepatic immune disorders. However, the role of TLR5 has not yet been investigated in experimental models of concanavalin A (Con A)–mediated liver injury. Here, we show that TLR5 is highly up‐regulated in the hepatic mononuclear cells of mice during Con A–induced hepatitis. Increased mortality and liver histopathology of TLR5‐deficient mice correlated with excessive production of proinflammatory cytokines, suggesting that TLR5 knockout mice were more susceptible to Con A–induced hepatitis. We also report that administration of CBLB502, an exogenous TLR5 agonist, substantially alleviated Con A–mediated hepatitis in wild‐type mice as shown by increased survival rates, reduced aminotransferase and proinflammatory cytokine production, impaired lymphocyte infiltration, and ameliorated hepatocyte necrosis and/or apoptosis. Mechanistic studies revealed that CBLB502 acts as a negative regulator in limiting T‐cell/natural killer T‐cell activity and cytokine production in the Con A–hepatitis model. Bone marrow transplantation experiments showed that TLR5 in bone marrow–derived cells contributed to the hepatoprotective efficacy of CBLB502 against Con A–induced liver injury. Moreover, interleukin‐6 elevation induced by CBLB502 is an important protective factor against Con A–induced liver injury. In addition, we demonstrate that CBLB502 suppresses α‐galactosylceramide‐induced natural killer T cell–dependent inflammatory liver injury. Conclusion : The TLR5 signaling pathway plays an important role in T cell–mediated hepatic injury and may be exploited for therapeutic treatment of inflammatory liver diseases. (H epatology 2017;65:2059‐2073).
Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer—Reply
Authors: Karla V. Ballman, Linda M. McCall, Armando E. Giuliano
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Taxes and Sugar-Sweetened Beverages
Authors: Lisa M. Powell, Matthew L. Maciejewski
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of Birth Weight on Lung Function and Exhaled Nitric Oxide in A Cohort of Asian Children at Six Years of Age
Authors: Wan-Fang Lee, Chun-Chun Gau, I-Chun Lu, Li-Lun Lin, Chao-Yi Wu, Hui-Ju Tsai, Tsung-Chieh Yao
Journal: Journal of Allergy and Clinical Immunology (2018)
Lithium and Dementia—Reply
Authors: Lars Vedel Kessing, Per Kragh Andersen, Annette Kjær Ersbøll
Journal: JAMA Psychiatry (2018)

In Reply Two comments by Sachdev and by Uzoigwe et al have addressed influences of latitude and other potential confounding factors in our study on the association between lithium in drinking water and the incidence of dementia.1
IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3− effector T cells
Authors: Valérie Dardalhon, Amit Awasthi, Hyoung Kwon, George Galileos, Wenda Gao, Raymond A Sobel, Meike Mitsdoerffer, Terry B Strom, Wassim Elyaman, I-Cheng Ho, Samia Khoury, Mohamed Oukka, Vijay K Kuchroo
Journal: Nature Immunology (2008)
In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional
Authors: S. Altrichter, T. Hawro, M. Liedtke, G. Holtappels, C. Bachert, P. S. Skov, M. Maurer
Journal: Allergy (2018)

Abstract Background Chronic spontaneous urticaria ( CSU ) is a frequent disorder with recurrent itchy wheals and/or angioedema. Despite the known effectiveness of omalizumab therapy, the relevant IgE antigens are largely unknown. Recently, increased rates of elevated levels of IgE towards Staphylococcus aureus enterotoxins ( SE s) were described in CSU . Aim To assess the prevalence and functional relevance of IgE to SE s in CSU . Method We investigated serum levels of IgE against SE s in 49 CSU patients and in 15 CSU patients additional specific IgE to SE components and basophil histamine release ( BHR ). Sera of 15 healthy controls ( HC s) served as control group. Results Twenty‐five (51%) of the CSU patients had detectable levels of SE ‐IgE as compared to 5 (33%) of HC s. Specific IgE to one of the SE s, Staphylococcus enterotoxin B ( SEB ), was present in 5 (33%) of 15 randomly selected CSU patients vs 3 (20%) of HC . Total IgE serum levels in CSU patients were significantly correlated with SE ‐IgE ( r = .52, P &lt; .001) and SEB ‐IgE ( r = .54, P = .04) serum concentrations. Interestingly, SEB ‐IgE levels were strongly correlated with disease activity ( UAS day) in CSU patients ( r = .657, P = .01). Furthermore, BHR in response to SEB was significantly higher in basophils loaded with the serum of CSU patients compared to HC ( P &lt; .05) and was clinically correlated with duration of disease ( r &gt; .51, P &lt; .05). Discussion IgE against SE s may contribute to the pathogenesis of CSU in a subpopulation of patients. Its role and relevance in the pathophysiology of CSU need to be further analysed.
An Immature Immunophenotype (CD34pos, CD38dim, nTdTdim) on Malignant B-Cell Precursor Blasts at Diagnosis Predicts High Minimal Residual Disease in BCP-ALL
Authors: Signe Modvig, Nina Friesgaard Øbro, Susanne Rosthøj, Gitte W Jürgensen, Kjeld Schmiegelow, Hanne Vibeke Marquart
Journal: Blood (2016)
Spanish Fly—Cantharidin’s Alter Ego
Authors: Benjamin Falck
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Reply to Smith <i>et al.</i>: An Argument for the Protocolized Screening and Management of Post-Extubation Stridor
Authors: Jonathon D. Truwit, Timothy D. Girard, Waleed Alhazzani, John P. Kress, Daniel R. Ouellette, Gregory A. Schmidt, Peter E. Morris
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32
Authors: Verena Niederberger, Angela Neubauer, Philippe Gevaert, Mihaela Zidarn, Margitta Worm, Werner Aberer, Hans Jørgen Malling, Oliver Pfaar, Ludger Klimek, Wolfgang Pfützner, Johannes Ring, Ulf Darsow, Natalija Novak, Roy Gerth van Wijk, Julia Eckl-Dorna, Margarete Focke-Tejkl, Milena Weber, Hans-Helge Müller, Joachim Klinger, Frank Stolz, Nora Breit, Rainer Henning, Rudolf Valenta
Journal: Journal of Allergy and Clinical Immunology (2018)

BM32 is a grass pollen allergy vaccine based on recombinant fusion proteins consisting of nonallergenic peptides from the IgE-binding sites of the 4 major grass pollen allergens and the hepatitis B preS protein.We sought to study the safety and clinical efficacy of immunotherapy (allergen immunotherapy) with BM32 in patients with grass pollen-induced rhinitis and controlled asthma.A double-blind, placebo-controlled, multicenter allergen immunotherapy field study was conducted for 2 grass pollen seasons. After a baseline season, subjects (n = 181) were randomized and received 3 preseasonal injections of either placebo (n = 58) or a low dose (80 μg, n = 60) or high dose (160 μg, n = 63) of BM32 in year 1, respectively, followed by a booster injection in autumn. In the second year, all actively treated subjects received 3 preseasonal injections of the BM32 low dose, and placebo-treated subjects continued with placebo. Clinical efficacy was assessed by using combined symptom medication scores, visual analog scales, Rhinoconjunctivitis Quality of Life Questionnaires, and asthma symptom scores. Adverse events were graded according to the European Academy of Allergy and Clinical Immunology. Allergen-specific antibodies were determined by using ELISA, ImmunoCAP, and ImmunoCAP ISAC.Although statistical significance regarding the primary end point was not reached, BM32-treated subjects, when compared with placebo-treated subjects, showed an improvement regarding symptom medication, visual analog scale, Rhinoconjunctivitis Quality of Life Questionnaire, and asthma symptom scores in both treatment years. This was accompanied by an induction of allergen-specific IgG without induction of allergen-specific IgE and a reduction in the seasonally induced increase in allergen-specific IgE levels in year 2. In the first year, more grade 2 reactions were observed in the active (n = 6) versus placebo (n = 1) groups, whereas there was almost no difference in the second year.Injections of BM32 induced allergen-specific IgG, improved clinical symptoms of seasonal grass pollen allergy, and were well tolerated.
Detection of mcr-4 positive Salmonella enterica serovar Typhimurium in clinical isolates of human origin, Italy, October to November 2016
Authors: Edoardo Carretto, Flavia Brovarone, Paola Nardini, Giuseppe Russello, Daniela Barbarini, Stefano Pongolini, Carlo Gagliotti, Alessandra Carattoli, Mario Sarti
Journal: Eurosurveillance (2018)

In this study we report the detection of the recently described mcr-4 gene in two human isolates of Salmonella enterica serovar Typhimurium. The strains were isolated from faecal samples of two Italian patients with gastroenteritis, collected in 2016. The identified mcr-4 genes (variant mcr-4.2) differed from the mcr-4 gene originally described in a Salmonella strain of swine origin from Italy. Salmonella species could represent a hidden reservoir for mcr genes.
Abstract 14621: Deviation of Three Methods to Estimate 24-h Urinary Sodium Excretion From Spot Urine Samples in Individuals.
Authors: Huanhuan Liu, Yu Tian, Long Zhou, Xiaoxiao Wen, Min Guo, Zhengxiong Yang, Liancheng Zhao
Journal: Circulation (2016)

Introduction:  Twenty-four-hour (24-h) urine collection is widely regarded as the gold standard for evaluating sodium (Na) intake. As a convenient alternative, spot urine method has been proposed to estimate 24-h urinary Na excretion, but its reliability remains highly controversial. The aim of the study was to assess the accuracy and deviation of three commonly used methods--- Kawasaki (K), INTERSALT (I) and Tanaka (T) for estimating 24-h urinary Na excretion using spot urine samples against measured 24-h urinary Na excretion in Chinese female adults.   Methods:  A total of 144 community housewives were enrolled in baseline investigation of a salt reduction program. Both a spot and a 24-h urine sample were collected for each participant and Na was measured in all samples. K, I and T equations were respectively used to estimate 24-h urinary Na excretion from spot urine samples. The correlation and difference between the measured and estimated 24-h Na excretions were then explored.   Results:  The analysis included 139 participants aged 51±8 years after exclusion of reported incomplete collections (n=2) and 24-h urine volume   Conclusions:  Although the correlation between the measured and estimated 24-h Na excretions was moderate, estimate of 24-h urinary Na excretion using spot urine samples showed large bias and might lead to misclassification in individuals.
Three-Dimensional Adipose Tissue Imaging Reveals Regional Variation in Beige Fat Biogenesis and PRDM16-Dependent Sympathetic Neurite Density
Authors: Jingyi Chi, Zhuhao Wu, Chan Hee J. Choi, Lily Nguyen, Saba Tegegne, Sarah E. Ackerman, Audrey Crane, François Marchildon, Marc Tessier-Lavigne, Paul Cohen
Journal: Cell Metabolism (2018)
Keeping Tumors Out of the MAPK Fitness Zone
Authors: David F. Stern
Journal: Cancer Discovery (2018)

Abstract Summary: Greatest fitness of tumor cell subclones in patients undergoing MAPK-targeting therapies requires just-right levels of MAPK pathway signaling. New therapeutic approaches induce tumor cell death by intensifying MAPK signaling induced by inhibitor withdrawal in combination with DNA damage, or prevent selection of resistant clones with a steep fitness barrier imposed by triple combination of BRAF, MEK, and ERK inhibitors. Cancer Discov; 8(1); 20–3. ©2018 AACR. See related article by Hong et al., p. 74.
STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy
Authors: Jin-Fei Chen, Peng Wu, Rui Xia, Jian Yang, Xin-Ying Huo, Dong-Ying Gu, Cui-Ju Tang, Wei De, Fen Yang
Journal: Molecular Cancer (2018)

Long noncoding RNAs (lncRNAs) are an important class of functional regulators involved in human cancers development, including gastric cancer (GC). Studying aberrantly expressed lncRNAs may provide us with new insights into the occurrence and development of gastric cancer by acting as oncogenes or tumor suppressors. In this study, we aim to examine the expression pattern of lncRNA HAGLROS in GC and its clinical significance as well as its biological role in tumor progression. Bioinformatics analysis and qRT-PCR were performed to detect the relative expression of HAGLROS in GC tissues and cell lines. Gain or loss of function approaches were used to investigate the biological functions of HAGLROS. The effect of HAGLROS on proliferation was evaluated by MTT, colony formation assay and nude mouse xenograft model. Wound healing and Transwell assays were used to study the invasion and migration of GC cells. FISH, RIP, RNA-seq, Luciferase report assays, RNA pulldown and Western blot were fulfilled to measure molecular mechanisms. Results are shown as means ± S.D. and differences were tested for significance using Student's t-test (two-tailed). We screened out HAGLROS, whose expression was significantly increased and correlated with outcomes of GC patients by publicly available lncRNAs expression profiling and integrating analyses. Exogenous down-regulation of HAGLROS expression significantly suppressed the cell proliferation, invasion and migration. Mechanistic investigations showed that HAGLROS was a direct target of transcriptional factor STAT3. Moreover, HAGLROS knockdown decreased mTOR expression and increased autophagy-related genes ATG9A and ATG9B expression. Further investigation showed that HAGLROS regulated mTOR signals in two manners. In the one hand, HAGLROS competitively sponged miR-100-5p to increase mTOR expression by antagonizing miR-100-5p-mediated mTOR mRNA inhibition. On the other hand, HAGLROS interacted with mTORC1 components to activate mTORC1 signaling pathway which was known to be an important negative signal of autophagy. Here activation of mTORC1 signaling pathway by HAGLROS inhibited autophagy, thereby promoted excessive proliferation and maintained the malignant phenotype of GC cells. The present study demonstrates that HAGLROS overexpression contributes to GC development and poor prognosis and will be a target for GC therapy and further develop as a potential prognostic biomarker.
Abstract 19212: Clinical Outcomes More Than 12 Months After PCI in Diabetic Patients With or Without DAPT: Results From the FREEDOM Trial
Authors: Jean-Francois Tanguay, Valentin Fuster, Christopher E Buller, Marc Jolicoeur, Michel Pellerin, George Dangas, Taye H Hamza, Flora S Siami, Michael E Farkouh
Journal: Circulation (2016)

Background:  Diabetic patients have higher risks of recurrent events after PCI. The role of long term dual antiplatelet therapy (DAPT) in such patients remains uncertain.   Hypothesis:  DAPT therapy would be associated with reduced long-term major cardiovascular events.   Methods:  We evaluated this in the FREEDOM trial which compared PCI to CABG in diabetic patients with multi-vessels disease. We performed an analysis of all subjects who underwent PCI to assess the composite of all-cause mortality, nonfatal myocardial infarction and stroke from 12 months up to 5 years after PCI for patients on DAPT or ASA alone. We also assessed the occurrence of major bleeding onset in this PCI cohort.   Results:  Of the 951 patients who underwent PCI in the FREEDOM trial, 682 patients (n=357 on DAPT; n=325 ASA only) had no event at 12 months and were included in this analysis. There was a trend towards increased composite events in the DAPT group compared with the ASA group (adjusted HR:1.48; 95% CI:0.92-2.40,p=0.11). There was no difference in major bleeding from 12 months through 5 years follow-up. Although no significant differences in outcome were observed between the two groups (see table), the baseline characteristics, EuroSCORE, history of myocardial infarction and current smoker, were significantly different.   Conclusions:  In the FREEDOM trial, prolonged DAPT after 12 months after PCI was not associated with a reduction in the composite ischemic outcome. These findings may reflect decision-making around the use of DAPT in trial patients or unmeasured risk factors.